GB Patent

GB2580653A — Use of cannabinoids in the treatment of comorbidities associated with epilepsy

Assigned to GW Research Ltd · Expires 2020-07-29 · 6y expired

What this patent protects

Cannabidiol (CBD) is disclosed for use in the treatment of quality of life domains associated with epilepsy, preferably treatment resistant epilepsy, wherein the quality of life domain that is treated is one or more of attention/concentration, stigma item, general health, languag…

USPTO Abstract

Cannabidiol (CBD) is disclosed for use in the treatment of quality of life domains associated with epilepsy, preferably treatment resistant epilepsy, wherein the quality of life domain that is treated is one or more of attention/concentration, stigma item, general health, language and social activity and these are improved independent of seizure reduction. Preferably, the CBD is in the form of a highly purified extract of cannabis which comprises at least 98% (w/w) CBD or is present as a synthetic compound. Preferably, the CBD is a highly purified extract which comprises up to 0.1% THC and more preferably up to 1% CDB.

Drugs covered by this patent

Patent Metadata

Patent number
GB2580653A
Jurisdiction
GB
Classification
—
Expires
2020-07-29
Drug substance claim
No
Drug product claim
No
Assignee
GW Research Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.